110 related articles for article (PubMed ID: 15538952)
1. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS.
Shippy RA; Mendez D; Jones K; Cergnul I; Karpiak SE
BMC Psychiatry; 2004 Nov; 4():38. PubMed ID: 15538952
[TBL] [Abstract][Full Text] [Related]
2. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.
Gibbie T; Mijch A; Ellen S; Hoy J; Hutchison C; Wright E; Chua P; Judd F
HIV Med; 2006 Mar; 7(2):112-21. PubMed ID: 16420256
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness.
Rabkin JG; Rabkin R; Wagner G
J Clin Psychiatry; 1994 Mar; 55(3):92-7. PubMed ID: 7915270
[TBL] [Abstract][Full Text] [Related]
4. Nature of depression in patients with HIV/AIDS.
Judd F; Komiti A; Chua P; Mijch A; Hoy J; Grech P; Street A; Lloyd J; Williams B
Aust N Z J Psychiatry; 2005 Sep; 39(9):826-32. PubMed ID: 16168041
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
6. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
Schmidt PJ; Daly RC; Bloch M; Smith MJ; Danaceau MA; St Clair LS; Murphy JH; Haq N; Rubinow DR
Arch Gen Psychiatry; 2005 Feb; 62(2):154-62. PubMed ID: 15699292
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant treatment of depression in HIV-seropositive women.
Ferrando SJ; Rabkin JG; de Moore GM; Rabkin R
J Clin Psychiatry; 1999 Nov; 60(11):741-6. PubMed ID: 10584761
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study.
Shoval G; Nahshoni E; Gothelf D; Manor I; Golobchik P; Zemishlany Z; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(5):182-5. PubMed ID: 21926484
[TBL] [Abstract][Full Text] [Related]
9. Association of quality of life with major depressive disorder among people with HIV in South India.
Selvaraj V; Ross MW; Unnikrishnan B; Hegde S
AIDS Care; 2013; 25(2):169-72. PubMed ID: 22639937
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic validity of assessment scales for depression in patients with schizophrenia.
Kim SW; Kim SJ; Yoon BH; Kim JM; Shin IS; Hwang MY; Yoon JS
Psychiatry Res; 2006 Sep; 144(1):57-63. PubMed ID: 16904189
[TBL] [Abstract][Full Text] [Related]
11. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study.
Varia I; Venkataraman S; Hellegers C; Gersing K; Doraiswamy PM
Psychopharmacol Bull; 2007; 40(1):47-56. PubMed ID: 17285095
[TBL] [Abstract][Full Text] [Related]
12. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
Amsterdam JD; Shults J; Rutherford N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
[TBL] [Abstract][Full Text] [Related]
13. Depressive and conduct disorder symptoms in youth living with HIV: the independent and interactive roles of coping and neuropsychological functioning.
Salama C; Morris M; Armistead L; Koenig LJ; Demas P; Ferdon C; Bachanas P
AIDS Care; 2013; 25(2):160-8. PubMed ID: 22690655
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
15. An open-label, flexible-dose study of memantine in major depressive disorder.
Ferguson JM; Shingleton RN
Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
[TBL] [Abstract][Full Text] [Related]
16. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.
Connolly KR; Helmer A; Cristancho MA; Cristancho P; O'Reardon JP
J Clin Psychiatry; 2012 Apr; 73(4):e567-73. PubMed ID: 22579164
[TBL] [Abstract][Full Text] [Related]
18. Telephone-administered psychotherapy for depression.
Mohr DC; Hart SL; Julian L; Catledge C; Honos-Webb L; Vella L; Tasch ET
Arch Gen Psychiatry; 2005 Sep; 62(9):1007-14. PubMed ID: 16143732
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the Major Depression Inventory (MDI) and the Beck Depression Inventory (BDI) in severely depressed patients.
Konstantinidis A; Martiny K; Bech P; Kasper S
Int J Psychiatry Clin Pract; 2011 Mar; 15(1):56-61. PubMed ID: 22122690
[TBL] [Abstract][Full Text] [Related]
20. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
